Orbactiv FDA Approval History
FDA Approved: Yes (First approved August 6, 2014)
Brand name: Orbactiv
Generic name: oritavancin
Dosage form: Injection
Company: The Medicines Company
Treatment for: Skin and Structure Infection
Orbactiv (oritavancin) is a semi-synthetic lipoglycopeptide antibiotic for the treatment of acute bacterial skin and skin structure infections (ABSSSI).
Development timeline for Orbactiv
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.